How cell and gene therapies are transforming pharma deal-mak...

After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to deliver with the first generation of promising new cel

Kiadis sheds half its staff as lead cell therapy bombs

UK startup Ervaxx targets ‘dark matter’ of human genome

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Dr Elliot N

Building cell therapy leadership in Europe

In these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind the scenes insight into the company’s European operations, including building a new manufactur

Delivering innovative therapies with close industry-NHS part...

It was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE)